11:14 AM EDT, 03/13/2025 (MT Newswires) -- Kane Biotech ( KNBIF ) on Thursday said it received approval from the Internal Review Board (IRB) of the University of Miami Health System to launch a clinical study of Kane's prototype DispersinB acne cleanser for the treatment of mild to moderate cases of acne vulgaris.

The trial, which is expected to start mid-year, will involve up to 24 subjects and will take place at the University of Miami Miller School of Medicine.

"DispersinB represents a groundbreaking approach to tackling acne, and we believe it has the potential to significantly improve outcomes for millions of people struggling with this condition," said Marc Edwards, chief executive oOfficer. "This approval marks an important milestone as we continue advancing our mission to bring innovative, science-driven dermatological solutions to market."

The company's shares were last seen up $0.005 to $0.105 on the TSX Venture Exchange.